Loading...
3 results
Search Results
Now showing 1 - 3 of 3
- Screening for Fabry disease in patients with left ventricular noncompactionPublication . Azevedo, Olga; Marques, Nuno; Craveiro, Nuno; Pereira, Ana Rita; Antunes, Hugo; Reis, Liliana; Guerreiro, Rui Azevedo; Pontes dos Santos, Rui; Miltenberger-Miltenyi, Gabriel; Sousa, Nuno; Cunha, DamiãoIt is unclear whether left ventricular noncompaction (LVNC) is a distinct cardiomyopathy or a morphologic manifestation of different cardiomyopathies. We previously reported a case of LVNC in a Fabry disease (FD) patient, but it remains to be clarified whether LVNC is a cardiac manifestation of FD, a coincidental finding or an overdiagnosis, which has major therapeutic implications. This study aims to determine the prevalence of FD among patients with LVNC.
- Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: how to guide the diagnostic strategy?Publication . Azevedo, Olga; Marques, Nuno; Reis, Liliana; Cruz, Inês; Craveiro, Nuno; Antunes, Hugo; Lourenço, Carolina; Gomes, Renata; Guerreiro, Rui Azevedo; Faria, Ricardo; Sá, Fernando; Lima, Rui; Gaspar, Paulo; Faria, Rui; Miltenberger-Miltenyi, Gabriel; Sousa, Nuno; Cunha, DamiãoFabry disease (FD) is a treatable cause of hypertrophic cardiomyopathy (HCM). We aimed to determine the independent predictors of FD and to define a clinically useful strategy to discriminate FD among HCM.
- p.G360R is a pathogenic GLA gene mutation responsible for a classic phenotype of Fabry diseasePublication . Carvalho Silva, Daniela; Marques, Nuno; Azevedo, Olga; Miltenberger-Miltenyi, Gabriel; Bento, Dina; Guedes, Joao; Azevedo, Pedro; Bispo, Joao; Mota, Teresa; Fernandes, Raquel; Nzwalo, Hipólito; Cabrita, Ana; Ramos, André; de Jesus, IlidioThe authors report the case of a classic phenotype of Fabry disease in a 60-year-old male patient presenting with left ventricular hypertrophy and stroke. Genetic analysis revealed 2 GLA-gene variants, i.e., p.R356Q and p.G360R. This clinical case highlights that the finding of 2 or more GLA gene variants in a Fabry patient should lead to a careful evaluation in order to determine their exact role in the condition. This case also provides the first clinical evidence that the p.G360R mutation is pathogenic and responsible for a classic phenotype of Fabry disease. The clinical improvement following the initiation of enzyme replacement therapy reinforces the importance of Fabry disease awareness and diagnosis in patients exhibiting red flags, such as left ventricular hypertrophy and stroke.